1988
DOI: 10.1016/0006-3223(88)90103-5
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of psychosis, intermittent hyponatremia, and polydipsia (PIP Syndrome) using lithium and phenytoin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0
1

Year Published

1988
1988
2017
2017

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 54 publications
(15 citation statements)
references
References 12 publications
0
14
0
1
Order By: Relevance
“…We found several case series demonstrating an increase in serum sodium concentration after 2-7 days for urea (202,203,204,205,206), demeclocycline (207), loop diuretics in combination with oral NaCl (123,125,208), phenytoin (209) and fluid restriction (210). We also identified case series of patients experiencing an increase in serum sodium over a longer time period of up to 12 months for urea (211,212,213), up to 3 weeks for demeclocycline (214,215,216,217,218,219), up to 20 weeks for lithium (220), up to 150 days for furosemide with oral NaCl (221) and up to 30 days in phenytoin (220).…”
Section: Rationale † Why This Question?mentioning
confidence: 89%
“…We found several case series demonstrating an increase in serum sodium concentration after 2-7 days for urea (202,203,204,205,206), demeclocycline (207), loop diuretics in combination with oral NaCl (123,125,208), phenytoin (209) and fluid restriction (210). We also identified case series of patients experiencing an increase in serum sodium over a longer time period of up to 12 months for urea (211,212,213), up to 3 weeks for demeclocycline (214,215,216,217,218,219), up to 20 weeks for lithium (220), up to 150 days for furosemide with oral NaCl (221) and up to 30 days in phenytoin (220).…”
Section: Rationale † Why This Question?mentioning
confidence: 89%
“…Lithium, similarly to demeclocycline, blocks the action of vasopressin at the level of secondary transmitters launched by the activation of the vasopressin receptor. Lithium has been effective in preventing hyponatremia in patients with the PIP, however, due to the risk of kidney and thyroid damage, it cannot be widely recommended [58]. Although the results of older studies confirm that demeclocycline increases the level of sodium and reduces the frequency and severity of hyponatremia in patients with the PIP syndrome [59], the most recent randomised placebo-controlled trial conducted by Alexander et al [60] did not confirm the above findings.…”
Section: Treatmentmentioning
confidence: 42%
“…Lit, podobnie jak demeclocylina, blokuje działanie wazopresyny na poziomie wtórnych przekaźników uruchamianych przez aktywację receptora wazopresynowego. Lit okazał się skuteczny w zapobieganiu hiponatremii u pacjentów z PIP, jednak z uwagi na ryzyko uszkodzenia nerek i tarczycy nie może być szeroko rekomendowany [58]. Chociaż wyniki starszych badań potwierdzają, że demeclocyklina podnosi poziomu sodu i zmniejsza częstość oraz nasilenie epizodów hiponatremii u pacjentów z syndromem PIP [59], to nowsze randominizowane badanie kontrolowane placebo, przeprowadzone przez Alexander i wsp.…”
Section: Leczenieunclassified
“…However, the pathophysiology and pharmacologic therapy have never been well examined, despite the severity and potential mortality associated with this condition (Illowsky and Kirch 1988;de Leon et al 1994). The treatment of polydipsia in psychiatric inpatients has variously involved the use of demeclocycline, lithium, phenytoin, and propranolol to oppose the central release of vasopressin or renal action (Goldman and Luchins 1985;Vieweg et al 1985Vieweg et al , 1988. However, behavioral management and water restriction are currently the most effective strategies for treating polydipsia.…”
Section: Introductionmentioning
confidence: 98%